Paris, Jun 29 (EFE) .- The French pharmaceutical multinational Sanofi will invest around 2 billion dollars in the next five years in the development of vaccines based on messenger RNA (mRNA) technology.
That investment will be made at a rate of about 400 million over the next five years, the multinational said in a statement on Tuesday.
He added that Sanofi will have about 400 workers dedicated to research on this technology and its applications in centers in France, the United Kingdom and the United States.
The goal is to develop vaccines, beyond the current pandemic, to prevent diseases that generate “important medical needs.”
The company anticipates having at least six vaccine candidates with this technology by 2025.
“In the covid-19 pandemic, mRNA technology has revealed its potential to achieve the development of new vaccines at an unprecedented speed,” although there are still issues to be resolved such as thermal stability and improved tolerance, said the head of Sanofi global research, Jean-François Toussaint.
(c) EFE Agency
